{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T16:39:38Z","timestamp":1740155978270,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,1,6]],"date-time":"2015-01-06T00:00:00Z","timestamp":1420502400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1038\/nrurol.2014.369","type":"journal-article","created":{"date-parts":[[2015,1,6]],"date-time":"2015-01-06T08:48:45Z","timestamp":1420534125000},"page":"74-76","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["From the genomic frontier to immunotherapeutics"],"prefix":"10.1038","volume":"12","author":[{"given":"Andrew T.","family":"Lenis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Chamie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,1,6]]},"reference":[{"key":"BFnrurol2014369_CR1","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315\u2013322 (2014).","DOI":"10.1038\/nature12965"},{"key":"BFnrurol2014369_CR2","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1158\/2159-8290.CD-13-0353","volume":"4","author":"N Wagle","year":"2014","unstructured":"Wagle, N.  et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 4, 546\u2013553 (2014).","journal-title":"Cancer Discov."},{"key":"BFnrurol2014369_CR3","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester, R. J.  et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49, 466\u2013477; discussion 623\u2013627 (2006).","journal-title":"Eur. Urol."},{"key":"BFnrurol2014369_CR4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ucl.2013.01.004","volume":"40","author":"AC James","year":"2013","unstructured":"James, A. C. & Gore, J. L. The costs of non-muscle invasive bladder cancer. Urol. Clin. North Am. 40, 261\u2013269 (2013).","journal-title":"Urol. Clin. North Am."},{"key":"BFnrurol2014369_CR5","doi-asserted-by":"publisher","unstructured":"Solsona, E.  et al. Sequential combination of mitomycin C plus bacillus Calmette-Gu\u00e9rin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial. Eur. Urol. \n                    http:\/\/dx.doi.org\/10.1016\/j.eururo.2014.09.026\n                    \n                  .","DOI":"10.1016\/j.eururo.2014.09.026"},{"key":"BFnrurol2014369_CR6","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/cncr.22588","volume":"109","author":"BA Inman","year":"2007","unstructured":"Inman, B. A.  et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 109, 1499\u20131505 (2007).","journal-title":"Cancer"},{"key":"BFnrurol2014369_CR7","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nature13904","volume":"515","author":"T Powles","year":"2014","unstructured":"Powles, T.  et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558\u2013562 (2014).","journal-title":"Nature"},{"key":"BFnrurol2014369_CR8","first-page":"202335","volume":"28","author":"KM Mahoney","year":"2014","unstructured":"Mahoney, K. M. & Atkins, M. B. Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park) 28, 202335 (2014).","journal-title":"Oncology (Williston Park)"},{"key":"BFnrurol2014369_CR9","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1002\/cncr.24052","volume":"115","author":"JL Gore","year":"2009","unstructured":"Gore, J. L.  et al. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis. Cancer 115, 988\u2013996 (2009).","journal-title":"Cancer"},{"key":"BFnrurol2014369_CR10","doi-asserted-by":"publisher","unstructured":"Chamie, K.  et al. Quality of diagnostic staging in patients with bladder cancer: a process\u2013outcomes link. Cancer \n                    http:\/\/dx.doi.org\/10.1002\/cncr.29071\n                    \n                  .","DOI":"10.1002\/cncr.29071"}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2014.369.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2014.369","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2014.369.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T05:04:41Z","timestamp":1684472681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrurol.2014.369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,6]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["BFnrurol2014369"],"URL":"https:\/\/doi.org\/10.1038\/nrurol.2014.369","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"type":"print","value":"1759-4812"},{"type":"electronic","value":"1759-4820"}],"subject":[],"published":{"date-parts":[[2015,1,6]]},"assertion":[{"value":"6 January 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}